ACAD - ACADIA Pharmaceuticals Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
16.87
-0.59 (-3.38%)
At close: 4:00PM EDT

16.87 0.00 (0.00%)
After hours: 4:35PM EDT

Stock chart is not supported by your current browser
Previous Close17.46
Open17.52
Bid16.80 x 1400
Ask16.90 x 4000
Day's Range16.77 - 17.63
52 Week Range14.51 - 41.20
Volume2,336,686
Avg. Volume3,253,031
Market Cap2.106B
Beta4.12
PE Ratio (TTM)N/A
EPS (TTM)-2.07
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est47.29
Trade prices are not sourced from all markets
  • Business Wire9 hours ago

    INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of ACADIA Pharmaceuticals Inc. Investors

    Law Offices of Howard G. Smith continues its investigation on behalf of ACADIA Pharmaceuticals Inc. (“ACADIA” or the “Company) (NASDAQ: ACAD) investors concerning the Company and its officers’ possible violations of federal securities laws. On April 9, 2018, CNN reported that “[p]hysicians, medical researchers and other experts told CNN that they worried that [Nuplazid] had been approved too quickly, based on too little evidence that it was safe or effective.” On this news, ACADIA’s share price fell more than 23% on April 9, 2018, thereby injuring investors. Then, on April 25, 2018, CNN reported that the U.S. Food and Drug Administration was re-examining the safety of Nuplazid, which was approved “despite concerns that not enough was known about the drug’s risks.” On this news, ACADIA’s share price fell nearly 22% on April 25, 2018, thereby further injuring investors.

  • See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
    Markit2 days ago

    See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

    This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on June 26. Over the last one-month, outflows of investor capital in ETFs holding ACAD totaled $2.13 billion.

  • Business Wire3 days ago

    Glancy Prongay & Murray LLP Announces Investigation on Behalf of ACADIA Pharmaceuticals Inc. Investors (ACAD)

    Glancy Prongay & Murray LLP (“GPM”) announces that it has commenced an investigation on behalf of ACADIA Pharmaceuticals Inc. (“ACADIA” or the “Company”) (NASDAQ: ACAD) investors concerning the Company and its officers’ possible violations of federal securities laws. On April 9, 2018, CNN reported that “[p]hysicians, medical researchers and other experts told CNN that they worried that [Nuplazid] had been approved too quickly, based on too little evidence that it was safe or effective.” On this news, ACADIA’s share price fell more than 23% on April 9, 2018, thereby injuring investors. Then, on April 25, 2018, CNN reported that the U.S. Food and Drug Administration was re-examining the safety of Nuplazid, which was approved “despite concerns that not enough was known about the drug’s risks.” On this news, ACADIA’s share price fell nearly 22% on April 25, 2018, thereby further injuring investors.

  • 5 Big Pharma Stocks Investors Love Right Now
    InvestorPlace3 days ago

    5 Big Pharma Stocks Investors Love Right Now

    News of positive clinical data for its Alzheimer’s study lifted the entire biotechnology sector. Oddly enough, markets largely ignored pharmaceutical stocks, choosing instead to invest in the riskier biotech sector. The following are Big Pharma stocks that should be on the radar of most investors.

  • Better Buy: Acadia Pharmaceuticals vs. Eli Lilly
    Motley Fool3 days ago

    Better Buy: Acadia Pharmaceuticals vs. Eli Lilly

    Which stock wins in a battle between a small, beaten-down biotech and an established major drugmaker?

  • PR Newswire5 days ago

    Hagens Berman Alerts Investors in ACADIA Pharmaceuticals Inc. (ACAD) to the Firm's Investigation of Possible Disclosure Violations

    SAN FRANCISCO , July 11, 2018 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) to the firm's investigation of possible securities law violations.  ...

  • Business Wire7 days ago

    INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of ACADIA Pharmaceuticals Inc. Investors

    Law Offices of Howard G. Smith announces an investigation on behalf of ACADIA Pharmaceuticals Inc. (“ACADIA” or the “Company”) (NASDAQ: ACAD) investors concerning the Company and its officers’ possible violations of federal securities laws. On April 9, 2018, CNN reported that “[p]hysicians, medical researchers and other experts told CNN that they worried that [Nuplazid] had been approved too quickly, based on too little evidence that it was safe or effective.” On this news, ACADIA’s share price fell more than 23% on April 9, 2018, thereby injuring investors. Then, on April 25, 2018, CNN reported that the U.S. Food and Drug Administration was re-examining the safety of Nuplazid, which was approved “despite concerns that not enough was known about the drug’s risks.” On this news, ACADIA’s share price fell nearly 22% on April 25, 2018, thereby further injuring investors.

  • InvestorPlace7 days ago

    Why ACADIA Pharmaceuticals Stock Is Falling Today

    ACADIA Pharmaceuticals (NASDAQ:ACAD) stock fell more than 6% on Monday as one of the company’s drugs is being investigated for its efficacy.

  • GlobeNewswire7 days ago

    Bragar Eagel & Squire, P.C. is Investigating ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) on Behalf of Stockholders and Encourages Investors to Contact the Firm

    NEW YORK, July 09, 2018-- Bragar Eagel & Squire, P.C. is investigating potential claims against ACADIA Pharmaceuticals Inc.. Our investigation concerns whether ACADIA violated the federal securities laws ...

  • GlobeNewswire7 days ago

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of ACADIA Pharmaceuticals Inc.

    NEW YORK, July 09, 2018-- Levi & Korsinsky announces it has commenced an investigation of ACADIA Pharmaceuticals Inc. concerning possible violations of federal securities laws.. On April 9, 2018, ACADIA ...

  • ACCESSWIRE7 days ago

    Today's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Ionis Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / July 9, 2018 / U.S. equities posted solid gains on Friday, ending the week on a positive note, supported by a stronger-than-expected jobs report. The Dow Jones Industrial Average ...

  • The 3 Worst Biotech Stocks of 2018 (So Far)
    Motley Fool8 days ago

    The 3 Worst Biotech Stocks of 2018 (So Far)

    These biotech stocks have taken a beating this year. But are any of them ready to rebound?

  • Exploring Acadia Pharmaceuticals’ Promising Research Pipeline
    Market Realist11 days ago

    Exploring Acadia Pharmaceuticals’ Promising Research Pipeline

    Acadia Pharmaceuticals’ (ACAD) Nuplazid (pimavanserin) is commercialized in the US market for the treatment of hallucinations and delusions related to Parkinson’s disease psychosis. The company believes that it has the potential to avoid many of the side effects of existing antipsychotics, none of which have been approved by the FDA. Acadia Pharmaceuticals also believes that the drug can potentially address key medical needs in neuropsychological and psychiatric disorders in addition to Parkinson’s disease psychosis.

  • Here’s Why Analysts See a Major Upside in Acadia Pharmaceuticals
    Market Realist11 days ago

    Here’s Why Analysts See a Major Upside in Acadia Pharmaceuticals

    Acadia Pharmaceuticals (ACAD) is a biopharmaceutical company engaged in developing and bringing to market innovative medicines targeted at central nervous system disorders. Of the eight analysts covering Acadia Pharmaceuticals in July, seven have given the stock “buy” or higher recommendations, while one has given it a “hold” rating. The mean rating for the stock is 2, and its target price is $47.29, implying a potential upside of 193% over the stock’s trading price of $16.13 on July 2.

  • Analyzing the Financial Performance of Acadia Pharmaceuticals
    Market Realist11 days ago

    Analyzing the Financial Performance of Acadia Pharmaceuticals

    This increase was due to the 120% volume growth of Nuplazid sales aided by the higher selling price of the drug. For 2018 and 2019, Acadia Pharmaceuticals is expected to report revenues of $261.41 million and $421.44 million, respectively. The cost of sales incurred by Acadia Pharmaceuticals fell marginally from $2.26 million in Q1 2017 to $2.15 million in Q1 2018 due to higher manufacturing levels.

  • Insights into ACAD’s Bottom Line and Cash Flow Trends
    Market Realist11 days ago

    Insights into ACAD’s Bottom Line and Cash Flow Trends

    The company saw a net income of -$54.29 million in Q1 2018 compared to -$87.84 million in Q1 2017. This resulted in the company’s net income per share rising to -$0.44 in Q1 2018 from its net income per share of -$0.72 in Q1 2017.

  • See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
    Markit13 days ago

    See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

    This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on June 26. Index (PMI) data, output in the Healthcare sector is rising.

  • Acadia Pharma Moves Up on FDA Approval
    Market Realist17 days ago

    Acadia Pharma Moves Up on FDA Approval

    Today, Acadia Pharmaceuticals (ACAD) is trending higher on news of the FDA’s approval of a 34 mg capsule and 10 mg tablet of Nuplazid (pimavanserin) for patients with Parkinson’s disease psychosis-related hallucinations and delusions. The stock was up ~12% in pre-market trading.

  • Why Acadia Pharmaceuticals Is Soaring Today
    Motley Fool17 days ago

    Why Acadia Pharmaceuticals Is Soaring Today

    Shares pop after the company reports upbeat regulatory news. Here's what shareholders need to know.

  • ACADIA Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID® (Pimavanserin)
    Business Wire17 days ago

    ACADIA Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID® (Pimavanserin)

    ACADIA Pharmaceuticals Inc. (ACAD) today announced FDA approval of a new capsule dose formulation and a new tablet strength of NUPLAZID (pimavanserin) to help in the treatment of patients living with hallucinations and delusions associated with Parkinson’s disease psychosis. The FDA approval of a 34 mg NUPLAZID capsule formulation will provide patients with the recommended 34 mg once daily dose in a single, small capsule, reducing patient pill burden versus the current administration of two 17 mg tablets. In addition, the FDA approval of a 10 mg tablet provides an optimized lower dosage strength in those patients who are concomitantly receiving strong cytochrome 3A4 inhibitors which can inhibit the metabolism of NUPLAZID.

  • See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
    Markit18 days ago

    See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

    Short interest is moderately high for ACAD with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on June 26. Over the last month, growth of ETFs holding ACAD is favorable, with net inflows of $6.37 billion.

  • ACCESSWIRE25 days ago

    Today's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Immunomedics

    NEW YORK, NY / ACCESSWIRE / June 21, 2018 / U.S. markets were mixed Wednesday as global trade concerns continue to be a focus. The Nasdaq and S&P 500 Index posted gains driven by deal making activities ...

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Clovis Oncology

    NEW YORK, NY / ACCESSWIRE / June 14, 2018 / U.S. markets fell Wednesday after the Federal Reserve raised interest rates and hinted at more increases were coming in 2018. The Dow Jones Industrial Average ...

  • Business Wirelast month

    ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 20, 2018

    ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the JMP Securities Life Sciences Conference on Wednesday, June 20, 2018, at 11:30 a.m. Eastern Time in New York City. ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders.

  • See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.